Skip to main content

Market Overview

Eagle Pharmaceuticals: Q1 Earnings Insights


Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected at $55.02 after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 16.83% year over year to $0.84, which beat the estimate of $0.57.

Revenue of $46,020,000 lower by 7.56% from the same period last year, which missed the estimate of $51,100,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Eagle Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: May 11, 2020

Time: 08:02 PM ET

Webcast URL:


Company's 52-week high was at $64.94

Company's 52-week low was at $33.80

Price action over last quarter: Up 25.07%

Company Profile

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.


Related Articles (EGRX)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at